Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakajima, T.
Right arrow Articles by Yanagisawa, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakajima, T.
Right arrow Articles by Yanagisawa, A.

Annals of Surgical Oncology, Vol 4, Issue 3 203-208, Copyright © 1997 by Society of Surgical Oncology

ARTICLES

Combined intensive chemotherapy and radical surgery for incurable gastric cancer

T. Nakajima, K. Ota, S. Ishihara, S. Oyama, M. Nishi, Y. Ohashi and A. Yanagisawa
Division of Gastrointestinal Surgery, Cancer Institute Hospital, Tokyo, Japan.

BACKGROUND: To improve the poor prognosis of patients with advanced incurable gastric cancer, intensive chemotherapy combined with radical surgery was used. PATIENTS AND METHODS: Thirty patients with incurable gastric cancer were treated with a combination of 5-fluorouracil (370 mg/m2) and leucovorin (30 mg/person), given intravenously for five consecutive days, followed by cisplatinum (70 mg/m2) and etoposide (70 mg/m2) on days 6 and 20, delivered through a catheter placed either in the aorta with its tip at the level of the ninth thoracic vertebra or in the celiac artery. This treatment (FLEP therapy) was repeated twice every 5 weeks. Radical or palliative surgery followed chemotherapy. RESULTS: The overall response rate to the chemotherapy was 50.0% (15 of 30 patients, 95% confidence limit 0.305-0.671). Nineteen patients (15 with a partial response, three showing no change, and one with progressive disease) underwent surgery. Of these, nine underwent curative surgery and 10 palliative surgery. The median survival time was 6.5 months overall, 12.7 months for responders, and 4.7 months for nonresponders. Long-term survivors were exclusively found among patients with distant lymph node metastasis treated by curative surgery (55.6% at 5 years). CONCLUSIONS: Favorable results of this small phase II study justify a phase III trial.


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
T. Yamao, K. Ohta, S. Ohyama, S. Ishihara, K. Chin, M. Maruyama, T. Takahashi, and T. Nakajima
A Preliminary Study of Preoperative Chemotherapy Combining Irinotecan and Cisplatin in Patients with Gastric Cancer with Unresectable Para-aortic Lymph Node Metastases
Jpn. J. Clin. Oncol., May 1, 2004; 34(5): 255 - 261.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
The Colorectal Cancer Chemotherapy Study Group of
Results of a Randomized Trial with or without 5-FU-based Preoperative Chemotherapy followed by Postoperative Chemotherapy in Resected Colon and Rectal Carcinoma
Jpn. J. Clin. Oncol., June 1, 2003; 33(6): 288 - 296.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Ueda, M. Iwahashi, M. Nakamori, M. Nakamura, I. Matsuura, H. Yamaue, and H. Tanimura
Carcinoembryonic Antigen-specific Suicide Gene Therapy of Cytosine Deaminase/5-Fluorocytosine Enhanced by the Cre/loxP System in the Orthotopic Gastric Carcinoma Model
Cancer Res., August 1, 2001; 61(16): 6158 - 6162.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the Society of Surgical Oncology.